Incyte Corporation

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
51.18 ^USD	-1.08%		-3.10%	-18.49%

Apr. 24	Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	MT
Apr. 23	Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call

Incyte : to Present at Upcoming Investor Conference

November 12, 2020 at 08:02 am EST

Incyte (Nasdaq:INCY) announced today that it will present at the 3^rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020 at 10:30 a.m. EST.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005041/en/

Latest news about Incyte Corporation

Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	Apr. 24	MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call	Apr. 23
Incyte Corporation entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.	Apr. 22	CI
BMO Capital Adjusts Price Target on Incyte to $56 From $64	Apr. 19	MT
Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
Trial of Insider Trading Case Against Former Medivation Employee Begins in California	Mar. 26	MT
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says	Mar. 12	MT
Transcript : Incyte Corporation - Shareholder/Analyst Call	Mar. 11
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)	Mar. 10	CI
Transcript : Incyte Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:50 AM	Mar. 04
Wall Street: a flurry of records, including that of the Nasdaq 'broad	Mar. 01	CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'.	Feb. 29	CF
Knight Therapeutics Announces Launch of Minjuvi in Brazil	Feb. 29	MT
Jefferies Initiates Incyte With Buy Rating, Price Target is $81	Feb. 23	MT
BMO Capital Adjusts Price Target on Incyte to $64 From $58, Keeps Market Perform Rating	Feb. 14	MT
Citigroup Adjusts Price Target on Incyte to $81 From $82, Keeps Buy Rating	Feb. 14	MT
JMP Securities Downgrades Incyte to Market Perform From Market Outperform	Feb. 14	MT
Truist Securities Adjusts Price Target on Incyte to $84 From $91, Maintains Buy Rating	Feb. 14	MT
Stifel Adjusts Price Target on Incyte to $68 From $67, Maintains Hold Rating	Feb. 14	MT
The market faces a choice	Feb. 14
RBC Lifts PT on Incyte to $65 From $63 on Model Updates Reflecting Monjuvi Integration, Slightly Improved Jakafi/Opzelura Sales Expectations; Sector Perform Kept	Feb. 14	MT
ANALYST RECOMMENDATIONS : Biogen, Gsk, Hp Inc, Palantir, Walt Disney...	Feb. 14
Incyte misses quarterly profit estimates due to higher costs	Feb. 13	RE
Incyte's Q4 Adjusted Earnings, Revenue Advance	Feb. 13	MT

Chart Incyte Corporation

Duration

Period

More charts

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT

More Strategies

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

51.18 USD

Average target price

75.2 USD

Spread / Average Target

+46.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-18.49%	11.62B
CSL LIMITED	-4.67%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B
INNOVENT BIOLOGICS, INC.	-7.13%	7.9B

Biopharmaceuticals

Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Incyte : to Present at Upcoming Investor Conference

EPS Revisions